These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20839263)

  • 1. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.
    Howells LM; Sale S; Sriramareddy SN; Irving GR; Jones DJ; Ottley CJ; Pearson DG; Mann CD; Manson MM; Berry DP; Gescher A; Steward WP; Brown K
    Int J Cancer; 2011 Jul; 129(2):476-86. PubMed ID: 20839263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines.
    Howells LM; Mitra A; Manson MM
    Int J Cancer; 2007 Jul; 121(1):175-83. PubMed ID: 17330230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis.
    Guo LD; Shen YQ; Zhao XH; Guo LJ; Yu ZJ; Wang D; Liu LM; Liu JZ
    Phytother Res; 2015 Mar; 29(3):357-65. PubMed ID: 25418925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer.
    Li L; Ahmed B; Mehta K; Kurzrock R
    Mol Cancer Ther; 2007 Apr; 6(4):1276-82. PubMed ID: 17431105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
    Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
    Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
    Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
    Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gercumin synergizes the action of 5-fluorouracil and oxaliplatin against chemoresistant human cancer colon cells.
    Genovese S; Epifano F; Preziuso F; Slater J; Nangia-Makker P; Majumdar APN; Fiorito S
    Biochem Biophys Res Commun; 2020 Jan; 522(1):95-99. PubMed ID: 31740005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin Enhances the Effects of 5-Fluorouracil and Oxaliplatin in Inducing Gastric Cancer Cell Apoptosis Both In Vitro and In Vivo.
    Zhou X; Wang W; Li P; Zheng Z; Tu Y; Zhang Y; You T
    Oncol Res; 2016 Jan; 23(1-2):29-34. PubMed ID: 26802648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
    Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
    Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Hu J; Cai G; Xu Y; Cai S
    Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
    Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
    J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
    Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
    Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.